Skip to the reading
The BPC
question kit

A guide to checking care

Your notes
Chapter index

Rules desk

An offer is not an approval.

Ask which rule supports the exact product being offered. A confident answer still needs a source.

There is no approved product.

By September 28, 2026, the U.S. medicines agency—the Food and Drug Administration (FDA)—had still not approved BPC-157.

The review also reported that the FDA found no country with an approved medicine containing BPC-157.

Read the basisFDA findings on approval, PDF

“Compounded” does not mean approved.

To compound a medicine is to prepare or mix it for an order.

This may be done by a pharmacist, doctor or a facility recorded with the FDA.

On September 26, 2026, compounded medicines remained without FDA approval.

The FDA does not assess the quality of these medicines, their benefits or their harms before they are offered to patients.

Read the basisFDA explanation of compounding

Keep the pharmacy’s licence check separate from the question about the ingredient.

A withdrawn request is not a green light.

The FDA page marked current April 22, 2026 says groups took back their requests for pharmacies to use BPC-157.

Taking back a request does not mean the FDA gave permission.

Read the basisFDA table of withdrawn requests

As of September 26, 2026, BPC-157 does not meet the federal ingredient rules for ordinary pharmacies making medicines to order.

Here, the ingredient is BPC-157 before it is mixed into a finished medicine.

An official drug standard is a written guide for identifying an ingredient and checking its quality.

The FDA found no such standard for BPC-157 as a drug ingredient.

If that standard is absent, the ingredient must either occur in an FDA-approved medicine or appear on the permitted pharmacy ingredient list.

BPC-157 meets neither of those conditions.

Read the basisFDA ingredient framework

Under these ingredient rules, taking back a request gives a pharmacy no permission to use BPC-157.

By September 26, 2026, the FDA still had not made clear what action it would take against pharmacies after a request was taken back.

A meeting is not a change in the rules.

Ahead of the agency’s advisory meeting in July 2026, FDA staff recommended that BPC-157 stay off the pharmacy ingredient list.

The FDA had published no record of the advisers’ votes as of September 28, 2026.

Read the basisFDA meeting materials

A vote by those advisers cannot change the ingredient list; the FDA must change the rule through a formal public process.

That process includes giving the public a chance to comment.

Read the basisFDA process for changing the list

Ask for the rule itself when someone points to a headline.